Pyrimidine Synthesis Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the pyrimidine synthesis inhibitor [epc] class. 12 active patents protecting 1 drugs. First major cliff: 2026. Daily refresh.

1
Drugs in class
12
Active US patents
68/100
Avg vulnerability
$1.1B
Annual revenue covered

Originators

Sanofi 12 patents

Cliff calendar — next 15 years

2
26
2
27
2
30
2
31
4
34

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aubagio
TERIFLUNOMIDE
 Sanofi 12 68 $1.1B 2026-09-12

Most attackable patents

Patent Drug Type Vuln Expiry
6794410 Aubagio method of use 85 2026-09-12
6794410 Aubagio method of use 85 2026-09-12
6794410 Aubagio other 80 2027-03-12
6794410 Aubagio other 80 2027-03-12
8802735 Aubagio other 68 2031-03-14
8802735 Aubagio other 68 2031-03-14
9186346 Aubagio method of use 62 2034-02-04
9186346 Aubagio method of use 62 2034-02-04
9186346 Aubagio other 62 2034-08-04
9186346 Aubagio other 62 2034-08-04

Strongest defences

Patent Drug Type Vuln Expiry
8802735 Aubagio formulation 53 2030-09-14
8802735 Aubagio formulation 53 2030-09-14
9186346 Aubagio other 62 2034-08-04
9186346 Aubagio other 62 2034-08-04
9186346 Aubagio method of use 62 2034-02-04
9186346 Aubagio method of use 62 2034-02-04
8802735 Aubagio other 68 2031-03-14
8802735 Aubagio other 68 2031-03-14
6794410 Aubagio other 80 2027-03-12
6794410 Aubagio other 80 2027-03-12

Related